Dr. Goutam Chakraborty is an Assistant Professor in the Department of Urology and the Department of Oncological Sciences, member of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. His expertise lies in cancer cell biology, with a particular focus on the functional genomics of oncogenic drivers that contribute to cancer progression and metastasis. During his graduate studies under the mentorship of Dr. Gopal Kundu at the National Centre for Cell Science in India, Dr. Chakraborty’s research focused on tumor angiogenesis. He later joined the Department of Cell Biology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York as a postdoctoral researcher, working with Dr. Filippo Giancotti’s group to investigate cellular plasticity, dormancy, and cancer metastasis. Subsequently, he joined Dr. Philip W. Kantoff’s team in the Department of Medicine at MSKCC, where he was promoted to faculty (Assistant Attending). In recognition of his contributions to DNA damage repair and prostate cancer research, Dr. Chakraborty received the Young Investigator Award (Class of 2019) from the Prostate Cancer Foundation (PCF). His research has played a pivotal role in identifying and establishing the functional impact of PIK3R1 mutations and metabolic reprogramming in lethal cancer. Since joining the Icahn School of Medicine at Mount Sinai, he has continued to advance the understanding of prostate cancer biology and explore innovative treatment strategies for patients. Throughout his career, Dr. Chakraborty has maintained a strong portfolio of federally and foundation-funded research in cancer biology. The success of his interdisciplinary research is evident in his peer-reviewed publications in high-impact journals such as Cell, Cancer Cell, Clinical Cancer Research, PNAS, Journal of Clinical Investigation, Cell Reports, Cancer Research, Oncogene, and others, as well as two patent filings. More recently, his work has focused on translational science, particularly in the identification and preclinical validation of novel targeted therapies, including combination therapies, for therapy-resistant metastatic cancer—addressing a critical need for effective treatments. Beyond research, Dr. Chakraborty has a passion for analog/film photography, traveling, and playing Badminton. He is also an avid Star Wars fan and a die-hard supporter of Mohun Bagan and Arsenal Football Club. Education: Bachelor of Science (B.Sc): Zoology (Hons):University of Calcutta, Kolkata, India. Master of Science. (M.Sc): Zoology: Darjeeling Government College, Darjeeling, India PhD: Council of Scientific & Industrial Research (CSIR-India) Fellow, National Centre for Cell Science, Pune, India. Post doctoral Research Fellowship: Memorial Sloan Kettering Cancer Center (MSKCC),New York, NY

Dr. Prathiksha Prabhakaraalva, originally from India, has a strong academic background in both Microbiology and Molecular Biology. She holds a master’s degree in biomedical science and a Ph.D. in Infectious Diseases from Nitte University, Mangaluru. In addition to her research expertise, she has over two years of experience as an Assistant Professor. Currently, Dr. Prabhakaraalva’s research focuses on investigating the impact of reprogrammed PIK3R1-insulin-glucose metabolism pathways due to PIK3R1 alterations in the progression of metastatic castration-resistant prostate cancer (mCRPC). Her work aims to elucidate the molecular mechanisms and cell signaling pathways that regulate the insulin-PI3K-glycolytic axis in prostate cancer. Outside the lab, she enjoys going for walks and catching up with friends.